Abbvie Inc

Abbvie Inc

ABBV

Market Cap$352.38B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Abbvie IncAbbvie Inc693.88%75%5.56

Earnings Call Q3 2024

October 30, 2024 - AI Summary

**Strong Sales Growth**: AbbVie's diverse portfolio achieved total net revenues of nearly $14.5 billion, reflecting a robust operational growth rate of 4.9%. Notably, the ex-Humira platform demonstrated an impressive growth of nearly 18%. Skyrizi and Rinvoq, key products in the immunology sector, saw combined sales projected to exceed $17 billion this year, surpassing initial expectations by $1.3 billion.
**Raised Revenue and EPS Guidance**: AbbVie raised its full-year revenue guidance by $500 million and adjusted earnings per share (EPS) guidance by $0.15, now expecting adjusted EPS between $10.90 and $10.94. This marks a total revenue increase of $1.8 billion since the initial guidance provided in February.
**Challenges with Humira**: Humira's global sales declined significantly, down 36.5% on an operational basis to $2.2 billion due to increasing biosimilar competition. While the erosion is in line with expectations, more Humira molecule volume is shifting to newer treatments than previously anticipated, contributing negatively to overall sales.

Exclusive for Stockcircle Pro members

Sign upSign Up
$212.14

Target Price by Analysts

24.5% upsideAbbvie Target Price DetailsTarget Price
$605.45

Current Fair Value

255.4% upside

Undervalued by 255.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$352.38 Billion
Enterprise Value$385.81 Billion
Dividend Yield$6.56 (3.88471177944862%)
Earnings per Share$2.73
Beta0.61
Outstanding Shares1,772,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio69.02
PEG-565.51
Price to Sales5.5
Price to Book Ratio2.03
Enterprise Value to Revenue6.95
Enterprise Value to EBIT25.57
Enterprise Value to Net Income75
Total Debt to Enterprise0.11
Debt to Equity5.96

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Abbvie Inc

CEO: Richard Gonzalez